The present study was carried out to establish the role of IgG subclasses in leprosy. IgG subclasses to Mycobacterium leprae sonicated antigens (MLSA) and phenolic glycolipid-I (PGL-I) were determined in 124 patients with active leprosy across the disease spectrum and in 76 cases with inactive disease after completion of chemotherapy. IgG2 antibodies were found to be the predominant subclass across the disease spectrum. Lepromatous patients showed elevated levels of IgGI. IgG3 antibody levels were higher in lepromatous than that in tuberculoid patients. Patients with erythema nodosum leprosum showed a significant fall in IgG3 antibody to MLSA. While chemotherapy induced a reduction in IgG1, IgG2 and IgG3 to PGL-I in almost all types of leprous patients, for MLSA the reduction was noticed for these subclasses only in lepromatous patients. IgG4 responses to these antigens were low through out the disease spectrum and did not alter with chemotherapy.

Keywords:
Leprosy, IgG subclasses, Chemotherapy, Erythema nodosum leptosum
1.
Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five-group spectrum. Int J Lepr 1966;34:255–273.
2.
Chaturvedi V, Sinha S, Girdhar BK, Katoch K, Bhatia AS, Sengupta U: Association of mycobacterial specific and M. leprae specific antibody levels with clinical activity in tuberculoid leprosy: A comparative study of three serological enzyme immunoassays. Lepr Rev 1991;62:122–133.
3.
Levis WR, Meeker HC, Schuller-Levis Sersen E, Brennan PJ, Fried P: Mycobacterial carbohydrate antigens for serological testing of patients with leprosy. J Infect Dis 1987;156:767–769.
4.
Sheela R, Shankernarayan NP, Ramu G, Muthukkaruppan VR: IgG subclass antibodies to mycobacterial sonicate and recombinant antigens in leprosy. Lepr Rev 1995;66:10–18.
5.
Hussain R, Kifayet A, Chiang TJ: Immunoglobulin G1 (IgG1) and IgG3 antibodies are markers of progressive disease in leprosy. Infect Immun 1995;63:410–415.
6.
Kifayet H, Hussain R: IgG subclass recognition of M. leprae antigens by IgG1 and IgG3 antibodies is distinct across the disease spectrum. Int J Lepr 1996;64:69–78.
7.
Lal RB, Ottesen EA: Enhanced diagnostic specificity in human filariasis by IgG4 antibody assessment. J Infect Dis 1988;158:1034–1037.
8.
Kwan-lim Ge, Forsyth KP, Maizels RM: Filarial specific IgG4 response correlates with active Wuchereria bancrofti infection. J Immunol 1990;145:4298–4305.
9.
Das MK, Beuria MK, Dash AP: Immunoglobulin E and G4 antibodies to infective larvae in a Wuchereria bancrofti endemic population. Int Arch Allergy Appl Immunol 1992;99:118–122.
10.
Evengard B, Hammerstrom L, Smith CIE, Johansson SGO, Linger E: Subclass distribution and IgE responses after treatment in human schistosomiasis. Clin Exp Immunol 1988;73:383–388.
11.
Ljungstrom I, Hammerstrom L, Kocieka W, Smith CIE: The sequential appearance of IgG subclasses and IgE during the course of Trichinella spiralis infection. Clin Exp Immunol 1988;74:230–235.
12.
Boyer AE, Tsang VCW, Eberherd ML, Zea-Flores G, Hightower A, Pilcher JB, Zea Flores R, Zhou W, Reimer CB: Evidence for IgG3 involvement in acquired immunity to Onchocerca volvolus and identification of possible immune associated antigens. J Immunol 1991;146:4001–4010.
13.
Skvaril F: IgG subclasses in viral infections. Monogr Allergy. Basel, Karger, 1986, vol 19, pp 134–143.
14.
Hammerstrom L, Smith CIE: IgG subclasses in bacterial infections. Monogr Allergy. Basel, Karger, 1986, vol 19, pp 122–133.
15.
Douglas JT, Steven LM, Fajardo T, Cellong RV, Madarang MG, Abalos RM, Steenberger GJ: The effects of chemotherapy on antibody levels in lepromatous patients. Lepr Rev 1988;59:127–135.
16.
Gelber RH, Lee F, Cho SN, Byrd S, Raj Gopalan K, Brennan PJ: Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Int J Lepr 1989;57:744–751.
17.
Roche PW, Britton WJ, Neupane K, Failbus SS, Cho SN, Theuvenet WJ: The response of chemotherapy of serum Mycobacterium leprae specific antigen in multibacillary leprosy patients. Am J Trop Med Hyg 1991;44:702–708.
18.
Roche PW, Britton WJ, Failbus SS, Neupane KD, Theuvenet WJ: Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr 1993;61:35–43.
19.
IAL: Clinical, histopathological and immunological features of the five-type classification approved by the Indian Association of Leprologists. Lepr India 1982;54:22–25.
20.
Finkelman FD, Katona IM, Mossman TR, Coffman RL: IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol 1988;140:1022–1027.
21.
Mutis T, Kraakman EM, Cornelisse YE, Haanen JBAG, Spits H, De Vries RRP, Ottenhoff THM: Analysis of cytokine production by mycobacterium-reactive T cells. Failure to explain Myco bacterium leprae specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. J Immunol 1993;150:4641–4651.
22.
Barret DJ, Ayoub EM: IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986;63:127–134.
23.
Dhandayuthapani S, Izumi S, Anandan D, Bhatia VN: Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Clin Exp Immunol 1992;88:253–257.
24.
Ulrich M, Rodriguez V, Centeno M, Convit J: Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen specific T cell anergy. Clin Exp Immunol 1995;100:54–58.
25.
Andreoli A, Brett SJ, Draper P, Payne SN, Graham AWR: Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Int J Lepr 1985;53:211–217.
26.
Cho SN, Kim JD, Cellona RV, Balagon MVF, Villahermosa LG, Fajardo TT Jr, Abalos RM, Walsh GP, Thole J, Brennan PJ: Association of antibodies to M. leprae and nerve antigens with lepra reactions in leprosy patients. Int J Lepr 1995;63:647–648.
27.
Jefferis R, Kumararatne DS: Selective IgG subclass deficiency quantification and clinical relevance. Clin Exp Immunol 1990;81:357–367.
28.
Kifayet A, Shahid F, Lucas S, Hussain R: Erythema nodosum leprosum is associated with up-regulation of polyclonal IgG1 antibody synthesis. Clin Exp Immunol 1996;106:447–453.
29.
Modlin RL, Melanson-Kaplain J, Young SMM: Learning from lesions: Patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA 1988;85:1213–1217.
30.
Naafas B: Leprosy reactions: New knowledge. Trop Geogre Med 1994;46:80–84.
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.